Industry Discovery & Development Partnership Program
Breakthrough T1D’s IDDP Program funds industry-led translational research and device development targeting key challenges in type 1 diabetes, including CVD, insulin dosing, ketone monitoring, and CGM–pump integration.
Funder: Breakthrough T1D
Due Dates: October 29, 2025 (LOI, CVD in T1D RFA) | January 13, 2026 (Full, CVD in T1D RFA) | November 5, 2025 (LOI, Insulin Dose RFA) | January 20, 2026 (Full, Insulin Dose RFA) | November 12, 2025 (LOI, Ketones RFA) | January 21, 2026 (Full, Ketones RFA) | September 2, 2026 (LOI, CGM–Pump RFA) | November 4, 2026 (Full, CGM–Pump RFA)
Funding Amounts: Up to $3,000,000 over 3 years (CVD RFA); up to $1,500,000 over 3 years (Ketones RFA); up to $900,000 over 3 years (CGM–Pump RFA); up to $750,000 over 2 years (Insulin Dose RFA); all via IDDP mechanism, no indirect costs, company match required.
Summary: Supports for-profit organizations advancing research and development of T1D therapies/devices in partnership with Breakthrough T1D, with a focus on high-priority, translatable projects.
Key Information: LOI required before full proposal; company matching funds required; indirect costs not allowed for IDDP applications.
Description
The Industry Discovery & Development Partnership (IDDP) Program from Breakthrough T1D is designed to fund for-profit organizations conducting research projects that closely align with Breakthrough T1D’s strategic priorities. The program leverages the commercial strengths of industry partners and Breakthrough T1D’s expertise in type 1 diabetes (T1D) research and advocacy to accelerate the development and translation of innovative solutions for T1D. Funding is available for collaborative projects, including clinical trials, device development, and translational research, with a clear path toward regulatory approval and commercialization. Current targeted areas include cardiovascular disease in T1D, clinical impact of insulin dose, ketones and continuous ketone monitoring, and combined CGM–pump devices.
